Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
Clinical trial NCT07295821 · RECRUITING
Trial details
- NCT number
- NCT07295821
- Sponsor
- AstraZeneca
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-01
- Primary completion
- 2029-05-30
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.